Connecting Innovation to Purpose

33 Rimonabant weight loss was not associated with reduction of lean mass in obese patients Rimonabant vs. placebo Phase 3 RIO study DEXA-scanned subgroup (n=146) Total body mass Total fat mass Fat mass/body mass Lean mass Unchanged Body composition was measured with body DEXA in a subset of patients in RIO Lipids. Decreases in the rimonabant 20 mg group relative to placebo were observed in the total body mass (p<0.001), the total body fat mass (p=0.001) and the fat mass/total body mass ratio (p=0.007). There was no statistically significant difference between the 20 mg and the placebo groups in lean mass loss between groups. Rimonabant NDA (page 21)

View entire presentation